|
1
|
Wong HH and Lemoine NR: Pancreatic cancer:
molecular pathogenesis and new therapeutic targets. Nature.
6:412–422. 2009.PubMed/NCBI
|
|
2
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics. Cancer J Clin. 60:277–300. 2010.
|
|
3
|
Ahrendt SA and Pitt HA: Surgical
management of pancreatic cancer. Oncology. 16:725–734.
2002.PubMed/NCBI
|
|
4
|
Burris HA III: Recent updates on the role
of chemotherapy in pancreatic cancer. Semin Oncol. 32:S1–S3. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mackenzie RP and McCollum AD: Novel agents
for the treatment of adenocarcinoma of the pancreas. Expert Rev
Anticancer Ther. 9:1473–1485. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bardeesy N and DePinho RA: Pancreatic
cancer biology and genetics. Nature. 2:897–909. 2002.
|
|
7
|
Buchholz M and Gress TM: Molecular changes
in pancreatic cancer. Expert Rev Anticancer Ther. 9:1487–1497.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Korc M, Chandrasekar B, Yamanaka Y, Friess
H, Buchier M and Beger HG: Overexpression of the epidermal growth
factor receptor in human pancreatic cancer is associated with
concomitant increases in the levels of epidermal growth factor and
transforming growth factor alpha. J Clin Invest. 90:1352–1360.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Watanabe M, Nobuta A, Tanaka J and Asaka
M: An effect of K-ras gene mutation on epidermal growth factor
receptor signal transduction in PANC-1 pancreatic carcinoma cells.
Int J Cancer. 67:264–268. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kobrin MS, Funatomi H, Friess H, Buchler
MW, Stathis P and Korc M: Induction and expression of
heparin-binding EGF-like growth factor in human pancreatic cancer.
Biochem Biophys Res Commun. 202:1705–1709. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yamanaka Y, Friess H, Kobrin MS, Buchler
M, Beger HG and Korc M: Coexpression of epidermal growth factor
receptor and ligands in human pancreatic cancer is associated with
enhanced tumor aggressiveness. Anticancer Res. 13:565–569.
1993.PubMed/NCBI
|
|
12
|
Jimeno A, Tan AC, Coffa J, Rajeshkumar NV,
Kulesza P, Rubio-Viqueira B, Wheelhouse J, Diosdado B, Messersmith
WA, Iacobuzio-Donahue C, Maitra A, Varella-Garcia M, Hirsch FR,
Meijer GA and Hidalgo M: Coordinated epidermal growth factor
receptor pathway gene overexpression predicts epidermal growth
factor receptor inhibitor sensitivity in pancreatic cancer. Cancer
Res. 68:2841–2849. 2008. View Article : Google Scholar
|
|
13
|
Kim IY, Kang YS, Lee DS, Park HJ, Choi EK,
Oh YK, Son HJ and Kim JS: Antitumor activity of EGFR targeted
pH-sensitive immunoliposomes encapsulating gemcitabine in A549
xenograft nude mice. J Control Release. 140:55–60. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
te Velde EA, Franke AC, van Hillegersberg
R, Elshof SM, de Weger RW, Borel Rinkes IH and van Diest PJ:
HER-familiy gene amplification and expression in resected
pancreatic cancer. Eur J Surg Oncol. 35:1098–1104. 2009.PubMed/NCBI
|
|
15
|
Yu D and Hung MC: Overexpression of ErbB2
in cancer and ErbB2-targeting strategies. Oncogene. 19:6115–6121.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Diana P, Stagno A, Barraja P, Carbone A,
Parrino B, Dall’Acqua F, Vedaldi F, Salvador A, Brun P,
Castagliuolo I, Issinger OG and Cirrincione G: Synthesis of
trazenoazaindoles: a new class of triazenes with antitumor
activity. Chem Med Chem. 6:1291–1299. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pham NA, Tsao MS, Cao P and Hedley DW:
Dissociation of gemcitabine sensitivity and protein kinase B
signaling in pancreatic ductal adenocarcinoma models. Pancreas.
35:16–26. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kreutzer JN, Ruzzene M and Guerra B:
Enhancing chemosensitivity to gemcitabine via RNA interference
targeting the catalytic subunits of protein kinase CK2 in human
pancreatic cancer cells. BMC Cancer. 10:4402010. View Article : Google Scholar
|
|
19
|
Yde CW, Olsen BB, Meek D, Watanabe N and
Guerra B: The regulatory beta subunit of protein kinase CK2
regulates cell-cycle progression at the onset of mitosis. Oncogene.
27:4986–4997. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen G, Kronenberger P, Teugels E and De
Grève J: Influence of RT-qPCR primer postion on EGFR interference
efficacy in lung cancer cells. Biol Proced Online.
11:132010.PubMed/NCBI
|
|
21
|
Walch A, Specht K, Bink K, Zitzelsberger
H, Braselmann H, Bauer M, Aubele M, Stein H, Siewert JR, Höfler H
and Werner M: Her-2/neu gene amplification, elevated mRNA
expression, and protein overexpression in the
metaplasia-dysplasia-adenocarcinoma sequence of Barrett’s
esophagus. Lab Invest. 81:791–801. 2001.PubMed/NCBI
|
|
22
|
Ali S, El-Rayes BF, Sarkar FH and Philip
PA: Simultaneous targeting of the epidermal growth factor receptor
and cyclooxygenase-2 pathways for pancreatic cancer therapy. Mol
Cancer Ther. 4:1943–1951. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schlieman MG, Fahy BN, Ramsamooj R,
Beckett L and Bold RJ: Incidence, mechanism and prognostic value of
activated AKT in pancreas cancer. Br J Cancer. 89:2110–2115. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sadasivam S, Gupta S, Radha V, Batta K,
Kundu TK and Swarup G: Caspase-1 activator Ipaf is a p53-inducible
gene involved in apoptosis. Oncogene. 24:627–636. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Orosco A, Fromigué O, Bazille C,
Entz-Werle N, Levillain P, Marie PJ and Modrowski D: Syndecan-2
affects the basal and chemotherapy-induced apoptosis in
osteosarcoma. Cancer Res. 67:3708–3715. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chang L and Karin M: Mammalian MAP kinase
signalling cascades. Nature. 410:37–40. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rennefhart U, Janakiraman M, Ollinger R
and Troppmair J: Stress kinase signaling in cancer: fact or
fiction? Cancer Lett. 217:1–9. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Marshall J: Clinical implications of the
mechanisms of epidermal growth factor receptor inhibitors. Cancer.
107:1207–1218. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bonder VM, Sweeney-Gotsch B, Andreeff M,
Mills GB and McConkey DJ: Inhibition of the phosphatidyl inositol
3′-kinase-AKT pathway induces apoptosis in pancreatic carcinoma
cells in vitro and in vivo. Mol Cancer Ther. 1:989–997. 2002.
|
|
30
|
Altomare DA, Tanno S, De Rienzo A,
Klein-Szanto AJ, Tanno S, Skele KL, Hoffman JP and Testa JR:
Frequent activation of AKT2 kinase in human pancreatic carcinomas.
J Cell Biochem. 87:470–476. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dent P, Yacoub A, Fisher PB, Hagan MP and
Grant S: MAPK pathways in radiation responses. Oncogene.
22:5885–5896. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lurje G and Lenz H: EGFR signaling and
drug discovery. Oncology. 77:400–410. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fujita H, Ohuchida K, Mizumoto K, Itaba S,
Ito T, Nakata K, Yu J, Kayashima T, Hayashi A, Souzaki R, Tajiri T,
Onimaru M, Manabe T, Ohtsuka T and Tanaka M: High EGFR mRNA
expression is a prognostic factor for reduced survival in
pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
Int J Oncol. 38:629–641. 2011.PubMed/NCBI
|
|
34
|
Eisenberg-Lerner A, Bialik S, Simon HU and
Kimchi A: Life and death partners: apoptosis, autophagy and the
cross-talk between them. Cell Death Diff. 16:966–975. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chadalapaka G, Jutooru I, Burghardt R and
Safe F: Drugs that target specificity proteins downregulate
epidermal growth factor receptor in bladder cancer cells. Mol
Cancer Res. 8:739–750. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nishi H, Neta G, Nishi KH, Akers LM,
Rikiyama T, Proctor KN, Murphy BA and Johnson AC: Analysis of the
epidermal growth factor receptor promoter: the effect of nuclear
factor-κB. Int J Mol Med. 11:49–55. 2003.
|
|
37
|
Schmedtje JF, Ji YS, Liu WL, DuBois RN and
Runge MS: Hypoxia induces cyclooxigenase-2 via the NF-κB p65
transcription factor in human vascular endothelial cells. J Biol
Chem. 272:601–608. 1997.PubMed/NCBI
|
